|
|
Volumn 61, Issue 5, 2012, Pages 739-745
|
|
Cancer immune escape: Implications for immunotherapy, Granada, Spain, October 3-5, 2011
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
BETA 2 MICROGLOBULIN;
CANCER VACCINE;
CYTOTOXIC T LYMPHOCYTE VACCINE;
DENDRITIC CELL VACCINE;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
MONOCLONAL ANTIBODY;
PEPTIDE VACCINE;
UNCLASSIFIED DRUG;
ANTIGEN PRESENTATION;
CANCER GROWTH;
CANCER IMMUNIZATION;
CANCER IMMUNOTHERAPY;
CANCER RESEARCH;
CONFERENCE PAPER;
CONTROLLED RELEASE FORMULATION;
HETEROZYGOSITY LOSS;
HUMAN;
HUMAN PAPILLOMAVIRUS TYPE 16;
IMMUNOGENICITY;
IMMUNOMODULATION;
IMMUNOSUPPRESSIVE TREATMENT;
MAJOR HISTOCOMPATIBILITY COMPLEX;
MELANOMA;
METASTASIS POTENTIAL;
MUTATIONAL ANALYSIS;
PAPILLOMAVIRUS INFECTION;
PHENOTYPE;
PRIORITY JOURNAL;
SPAIN;
TUMOR ESCAPE;
TUMOR MICROENVIRONMENT;
CANCER VACCINES;
HUMANS;
IMMUNOTHERAPY;
NEOPLASMS;
TUMOR ESCAPE;
TUMOR MICROENVIRONMENT;
|
|
EID: 84862499617
PISSN: 03407004
EISSN: 14320851
Source Type: Journal
DOI: 10.1007/s00262-012-1213-9 Document Type: Conference Paper |
|
Times cited : (8)
|
|
References (0)
|
